Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990976 | 0.96 | IDH1 (0.58) | IDH1KMT2ALMNAL3MBTL1POLB | |
| SCHEMBL11083861 | 0.95 | IDH1 (0.52) | IDH1KMT2ALMNAL3MBTL1POLB | |
| SCHEMBL11210510 | 0.91 | IDH1 (0.51) | IDH1KMT2ALMNAL3MBTL1POLB | |
| SCHEMBL11089279 | 0.91 | IDH1 (0.48) | IDH1KMT2ALMNAL3MBTL1PPARG | |
| SCHEMBL10646208 | 0.90 | IDH1 (0.50) | IDH1KMT2ALMNAL3MBTL1POLB | |
| SCHEMBL10967553 | 0.89 | IDH1 (0.46) | IDH1KMT2ALMNAL3MBTL1PPARG | |
| SCHEMBL11548487 | 0.88 | L3MBTL1 (0.63) | KMT2ALMNAL3MBTL1POLBEPHX2 | |
| SCHEMBL10755853 | 0.88 | IDH1 (0.45) | IDH1KMT2ALMNAL3MBTL1PPARG | |
| SCHEMBL11516273 | 0.88 | IDH1 (0.53) | IDH1KMT2ALMNAL3MBTL1POLB | |
| SCHEMBL21992625 | 0.86 | IDH1 (0.44) | IDH1KMT2APOLBPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4380661-A | HERBICIDES | HOFFMANN-LA ROCHE INC. (US) | 1983-04-19 | — | — | US | claimed |
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3599077-B1 | METHOD OF FORMING CONDUCTIVE THREE-DIMENSIONAL ARTICLES | XEROX CORP (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10821658-B2 | Conductive three-dimensional articles | XEROX CORPORATION (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
| US-20200031041-A1 | CONDUCTIVE THREE-DIMENSIONAL ARTICLES | Genesee Valley Innovations, LLC | 2020-01-30 | — | — | US | disclosed |
| EP-0247424-A1 | Propionic acid thiol ester derivatives, processes for their production and herbicidal compositions containing them | Tosoh Corporation (JP) | 1987-12-02 | — | — | EP | disclosed |
| EP-0201775-A2 | Derivative of propionic acid and selective herbicide containing the same | AGRO-KANESHO CO., LTD. (JP) | 1986-11-20 | — | — | EP | disclosed |
| US-4531969-A | Combatting growth of weeds | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-07-30 | — | — | US | disclosed |
| US-4380661-A | HERBICIDES | HOFFMANN-LA ROCHE INC. (US) | 1983-04-19 | — | — | US | disclosed |
| US-4332961-A | BENZYL ESTER OF 4-TRIFLUOROMETHYLPHENOXYPHENOXYALKANECARBOXYLIC ACID | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1982-06-01 | — | — | US | disclosed |
| US-4332960-A | (4-TRIFLUOROMETHYLPHENOXY) PHENOXY PROPIONATE | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-06-01 | — | — | US | disclosed |
| US-4314069-A | ESTERS OF A-(4-(4-TRIFLUOROMETHYL)PHENOXY)0PHENOXY)ALKANECARBOXYLIC ACIDS | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1982-02-02 | — | — | US | disclosed |
| US-4309562-A | SELECTIVE KILLING OF GRASSY WEEDS IN BROAD-LEAFED CROPS | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1982-01-05 | — | — | US | disclosed |
| US-4270948-A | (TRIFLUOROMETHYLPHENOXY)PHENOXYALKANE THIOCARBOXYLATE | ISHIHARA SANGYO KAISHA LTD. (JP) | 1981-06-02 | — | — | US | disclosed |
| US-4200587-A | HERBICIDES | HOFFMANN-LA ROCHE INC. (US) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | IDH1 2003/4885KMT2A 4842/4885LMNA 4533/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | IDH1 2003/4885KMT2A 4842/4885LMNA 4533/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | IDH1 2003/4885KMT2A 4842/4885LMNA 4533/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | IDH1 2003/4885KMT2A 4842/4885LMNA 4533/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | IDH1 2003/4885KMT2A 4842/4885LMNA 4533/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | IDH1 2003/4885KMT2A 4842/4885LMNA 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.